Total cohort | Athletes | Non-athletes | |
---|---|---|---|
Number of patients | 353 | 130 | 223 |
Age at diagnosis (years) | 17±11 | 11±7 | 20±12 |
Sex (male/female) | 154/199 | 70/60 | 84/139 |
Average QTc (ms) | 472±42 | 471±46 | 472±39 |
Genotype | |||
LQT1 | 182 (52%) | 74 (57%) | 108 (48%) |
LQT2 | 130 (37%) | 41 (32%) | 89 (40%) |
LQT3 | 37 (10%) | 11 (8%) | 26 (12%) |
Multiple | 4 (1%) | 4 (3%) | 0 (0%) |
Symptoms | 111 (31%) | 29 (22%) | 82 (37%) |
β-Blockers | 280 (79%) | 112 (87%) | 168 (75%) |
ICD | 78 (22%) | 20 (15%) | 58 (26%) |
Follow-up available (years) | 5.5±3.4 | 5.1±2.9 | 5.8±3.7 |
Ages, QTc at diagnosis and follow-up are reported as mean±SD.
ICD, implantable cardioverter defibrillators; LQT, long QT.